Generic competition isn’t just a legal event—it’s a business strategy.
For years, the public narrative around drug patents has been simple: a patent expires, generics arrive, prices fall. But the reality is more nuanced—and often more aggressive. In …

Patients aren’t asking “Can I switch?”—they’re asking “Will I be okay?”
If you’ve spent any time reading what people type into search bars, you’ll notice something: the questions aren’t theoretical. They’re personal. And they’re urgent.
A new post from…

Brand teams don’t lose to competitors—they lose to time. And time, in pharma, is often stolen quietly through “evergreening”: incremental formulation tweaks, new delivery mechanisms, method-of-use claims, and patent thickets that turn a clear path to g…

The Patent Cliff Isn’t Coming—It’s Already Here.
If you work in pharma strategy, you’ve heard the phrase “patent cliff” so often it can start to sound abstract. But the reality is brutally concrete: once exclusivity ends, revenue doesn’t just decline…

🚨 Drug patents are getting hit from an unexpected direction: AI that can read, reason, and move faster than the legal clock.
OpenAI’s GPT and Rosalind—tools built to accelerate biological understanding—are now being positioned as something more than…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the hardest part isn’t knowing that a threat is coming—it’s knowing when and how it will arrive.
Paragraph IV drug patent challenges are often des…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly what you’re really up against.
If you’re launching (or defending) a branded medicine in the Gulf Cooperation Council (GCC), you already know the …

Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to watch.
In pharma, the most expensive word in the room is often the quietest: extension.
A competitor doesn’t always need a breakthrough to protect revenue. Sometimes they just…